 | |
| Clinical data | |
|---|---|
| Trade names | Oxsoralen, Uvadex, 8-mop, others |
| Other names | xanthotoxin |
| AHFS/Drugs.com | Consumer Drug Information |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Extracorporeal, By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | ~2 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.516  |
| Chemical and physical data | |
| Formula | C12H8O4 |
| Molar mass | 216.192 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Methoxsalen (or Xanthotoxin, 8-methoxypsoralen) sold under the brand name Oxsoralen among others, is a medication used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to ultraviolet (UVA) light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. Levels of individual patient PUVA exposure were originally determined using the Fitzpatrick scale. The scale was developed after patients demonstrated symptoms of phototoxicity after oral ingestion of methoxsalen followed by PUVA therapy. Chemically, methoxsalen is a derivative of psoralen and belongs to a class of organic natural molecules known as furanocoumarins. They consist of coumarin annulated with furan. It can also be injected and used topically.
Natural sources
In 1947, methoxsalen was isolated (under the name "ammoidin") from the plant Ammi majus, bishop's weed.
In 1970, Nielsen extracted 8-methoxypsoralen from four species of the genus Heracleum in the carrot family Apiaceae, including Heracleum mantegazzianum and Heracleum sphondylium. An additional 32 species of the genus Heracleum were found to contain 5-methoxypsoralen (bergapten) or other furanocoumarins.
Biosynthesis
The biosynthetic pathway is a combination of the shikimate pathway, which produces umbelliferone, and the mevalonate pathway.
Synthesis of umbelliferone
Umbelliferone is a phenylpropanoid and as such is synthesized from L-phenylalanine, which in turn is produced via the shikimate pathway. Phenylalanine is lysated into cinnamic acid, followed by hydroxylation by cinnamate 4-hydroxylase to yield 4-coumaric acid. The 4-coumaric acid is again hydroxylated by cinnamate/coumarate 2-hydroxylase to yield 2,4-dihydroxy-cinnamic acid (umbellic acid) followed by a bond rotation of the unsaturated bond adjacent to the carboxylic acid group. Finally an intramolecular attack from the hydroxyl group of C2' to the carboxylic acid group closes the ring and forms the lactone umbelliferone.
Synthesis of methoxsalen
The biosynthetic route then continues with the activation of dimethylallyl pyrophosphate (DMAPP), produced via the mevalonate pathway, to form a carbo-cation via the cleavage of the diphosphates. Once activated, the enzyme umbelliferone 6-prenyltransferase catalyzes a C-alkylation between DMAPP and umbelliferone at the activated position ortho to the phenol, yielding demethylsuberosin. This is then followed by a hydroxylation catalyzed by the enzyme marmesin synthase to yield marmesin. Another hydroxylation is catalyzed by psoralen synthase to yield psoralen. A third hydroxylation by the enzyme psoralen 8-monooxygenase yields xanthotoxol which is followed by a methylation via the enzyme xanthotoxol O-methyltransferase and S-adenosyl methionine to yield methoxsalen.
Risks and side effects
Patients with high blood pressure or a history of liver problems are at risk for inflammation and irreparable damage to both liver and skin. The eyes must be protected from UVA radiation. Side effects include nausea, headaches, dizziness, and in rare cases insomnia.
Methoxsalen has also been classified as an IARC Group 1 carcinogen (known to cause cancer) but is only cancerous when combined with light - UVA radiation.
Society and culture
Author John Howard Griffin (1920–1980) used the chemical to darken his skin in order to investigate racial segregation in the American South. He wrote the book Black Like Me (1961) about his experiences.
References
- ^ "Uvadex". Therapeutic Goods Administration (TGA). 13 December 2019. Retrieved 25 August 2020.
- ^ "AusPAR: Methoxsalen". Therapeutic Goods Administration (TGA). 12 December 2019. Retrieved 17 September 2021.
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- "Uvadex- methoxsalen injection, solution". DailyMed. U.S. National Library of Medicine. Retrieved 17 September 2021.
- "Oxsoralen-Ultra- methoxsalen capsule, liquid filled". DailyMed. U.S. National Library of Medicine. Retrieved 17 September 2021.
- Fahmy IR, Abu-Shady H (1947). "Ammi majus Linn.; pharmacognostical study and isolation of a crystalline constituent, ammoidin". Quarterly Journal of Pharmacy and Pharmacology. 20 (3): 281–91, discussion 426. PMID 20273299.
- Marshall SR (June 2006). "Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?". Nature Clinical Practice. Oncology. 3 (6). Nature Publishing: 302–314. doi:10.1038/ncponc0511. PMID 16757968. S2CID 8441159.
- Nielsen BE (1970). Coumarins of Umbelliferous plants. Copenhagen: Royal Danish School of Pharmacy. Cited by Mitchell and Rook (1979).
- Mitchell J, Rook A (1979). Botanical Dermatology: Plants and Plant Products Injurious to the Skin. Vancouver: Greengrass. pp. 692–699. ISBN 978-0-88978-047-7.
- Dewick PM (2009). Medicinal Natural Products: A Biosynthetic Approach (3rd ed.). John Wiley & Sons. pp. 161, 164–165.
- "Known and Probable Human Carcinogens". American Cancer Society. Archived from the original on 30 September 2016.
- Mikkelson D (27 July 2003). "Death of John Howard Griffin". snopes.com. Snopes Media Group Inc.
| Drugs used for psoriasis (D05) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Topical |
| ||||||||
| Systemic |
| ||||||||
| |||||||||
| Types of coumarins | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aglycones |
| ||||||||||
| Glycosides | |||||||||||
| Derivatives |
| ||||||||||
| Oligomers | |||||||||||
| Synthetic | |||||||||||
